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Paracrine signaling mechanisms play a critical role in
both normal mammary gland development and breast
cancer. Dissection of these mechanisms using
genetically engineered mouse models has provided
significant insight into our understanding of the
mechanisms that guide intratumoral heterogeneity. In
the following perspective, we briefly review some of
the emerging concepts in this field and emphasize
why elucidation of these pathways will be important
for future progress in devising new and improved
combinatorial therapeutic approaches for breast and
other solid cancers.sity and supports the idea that tumors progress by punctu-Introduction
One of the basic tenets of developmental biology is that
there are signaling cells responsible for generating local fac-
tors and target cells that respond to these neighboring cues
to regulate cell fate and developmental outcome [1]. These
signaling interactions can be between tissue compartments
(for example, epithelial-stromal interactions) or within a
given tissue compartment (for example, interactions be-
tween epithelial cells). Accordingly, cell-cell interactions
and paracrine signaling play critical roles in the regulation
of tissue morphogenesis, including in mammary gland de-
velopment [2]. This review is focused on interactions be-
tween epithelial cells, although interactions with cells in
the microenvironment, especially cells of the immune sys-
tem, are equally important components of these paracrine
regulatory networks (for an excellent review, see [3]).
In systems biology, there has generally been a tendency
to overlook these types of interactions and instead to
model signal transduction pathways in a cell-autonomous* Correspondence: jrosen@bcm.edu
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2014manner. Although there has been increasing emphasis on
the interaction of breast cancer cells with their micro-
environment, less attention has been placed on under-
standing the potential of cell-cell and paracrine
interactions within the heterogeneous tumor environ-
ment. These signaling interactions likely shape the diverse
cellular phenotypes that constitute the heterogeneous
landscape within individual tumors.
In the past few years, deep sequencing of breast cancers
has revealed enormous intratumoral heterogeneity [4].
This heterogeneity has been hypothesized to arise in part
through branched Darwinian evolution of genetically di-
verse subclones that arise during tumor progression [5].
Single-cell analysis has revealed even greater genetic diver-
ated clonal expansions [6]. These diverse clones display
variability with respect to both their tumor propagation
ability and responses to therapy [7]. Tumors that display
the greatest degree of genetic instability are also often the
most refractory to treatment [8]. In addition to genetic di-
versity, the varied functional properties of cellular subpop-
ulations within tumors are influenced by epigenetic
factors. Though not mutually exclusive with the clonal se-
lection hypothesis, the cancer stem cell hypothesis posits
the existence of a self-renewing population of cells that
have ‘the developmental potential to recapitulate all the
cell types found in a given tissue’ [9]. Furthermore, a
‘niche’ microenvironment is thought to be important in
the regulation of stem cell quiescence and differentiation.
This niche may be composed of either additional tumor
cells or cells from the microenvironment, such as fibro-
blasts and endothelial cells, or both.
Given that different cellular subpopulations can show
large differences in regenerative behavior and treatment
response, both within a given tumor and across a collec-
tion of tumors, a better understanding of the relation-
ships among the different cell subpopulations within
breast cancers will be critical to the development of newntral Ltd. The licensee has exclusive rights to distribute this article, in any
n. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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mechanisms involved in this complex biology in breast
cancer is a daunting task, especially if (as suggested by
deep sequencing) each cancer may be unique. If each
tumor follows its own set of growth regulatory rules
based on its own cellular makeup and genetic/epigenetic
diversity, how can these differences be understood
within a unifying context?
An alternative complementary approach to unraveling
intratumoral heterogeneity is to better elucidate the be-
haviors of different cell populations during normal
mammary gland development. Unlike breast cancer, in
which the cells may have heterogeneous properties due
to various mutations, the ‘normal’ luminal and basal
mammary epithelial cell types that are composed of stem
and progenitor cells should have more predictable devel-
opmental behaviors [10]. Thus, as a first step in this
process, it would seem self-evident that the best way to
approach this problem is to try to understand the inter-
actions between the ligands and receptors in these differ-
ent compartments during mammary gland development.
Finally, since the output of a given signaling pathway
(for example, the Wnt and Notch pathways) will a priori
be cell context-dependent, studies to determine gene ex-
pression changes ideally should be performed on defined
cell subpopulations. In the following, we will briefly
highlight a few of the important concepts and pathways.Paracrine signaling pathways and mammary
gland development
The majority of mammary gland development occurs
post-natally and is regulated by both systemic hormones
and local growth factors. A role for paracrine signaling
pathways in mammary gland development was first sug-
gested by studies in which there was a dissociation of
the localization of estrogen receptor (ER)-positive and
progesterone receptor (PR)-positive cells from prolifera-
tive cells in the ductal epithelium of several mammalian
species [11-13] (Figure 1A). These descriptive studies
were complemented by elegant genetic studies in which
mammary gland chimeras were generated by transplant-
ing mixtures of wild-type mammary epithelial cells
(MECs) and ER- or PR-null MECs into the cleared fat
pads of recipient mice. In both cases, the presence of
wild-type cells rescued the null phenotype (that is, the
lack of alveologenesis observed with PR-null transplants
or the failure to obtain ductal outgrowths with ER-null
transplants) [14-16]. These studies represented formal
genetic proof that paracrine factors made by the wild-
type cells were acting on steroid receptor-null cells to fa-
cilitate normal ductal and alveolar morphogenesis. Thus,
studies of chimeric outgrowths in the mammary gland
are similar but not identical to the kinds of clonalanalyses performed in the Drosophila eye to distinguish
cell-autonomous from non-autonomous pathways.
A number of paracrine mediators have been identified
that might account for the effects of steroid hormones.
Receptor activator of nuclear factor kappa-B ligand
(RANKL), Wnt 4, and IGF-II were all identified as poten-
tial paracrine mediators of PR [17-19], whereas amphire-
gulin was suggested to be a critical paracrine mediator of
ER [20] (Figure 1A). Furthermore, several of these media-
tors have been shown to be required for progesterone-
and estrogen-induced proliferation in the mammary gland
both in genetically engineered mouse models [21] and
more recently in tissue microstructures isolated from pri-
mary human reduction mammoplasties [22]. Thus, these
hormonal mechanisms are apparently conserved across
species [22]. Mammary stem cells (MaSCs) have also been
shown to be sensitive to steroid hormones despite the lack
of steroid receptors in MaSCs [23]. Consistent with this
observation, progesterone-regulated RANKL and Wnt 4
have been demonstrated to induce mammary stem cell ex-
pansion [24]. More recently, progesterone-RANKL para-
crine signaling also has been shown to regulate Elf5
expression in luminal progenitors [25]. In these studies,
progesterone-induced side branching and the expansion
of Elf5+ mature luminal cells were prevented by inhibition
of RANKL action. Thus, steroid hormone-regulated para-
crine mechanisms may affect luminal and basal cells as
well as stem and progenitor cells, potentially in both
compartments.
Two independent studies performed in our laboratory
also illustrate the importance of paracrine signaling
mechanisms in the mammary gland. While investigating
the role of Hedgehog signaling in the mammary gland,
we showed that ectopic expression of the Hedgehog ef-
fector protein Smoothened (Smo) is commonly observed
in a subset of cells in early breast disease but that these
Smo-expressing cells are largely quiescent despite ele-
vated proliferation in the surrounding lesion [26]. When
a conditional allele of constitutively active Smo activated
by either a mouse mammary tumor virus or adenoviral-
Cre recombinase was used, high levels of proliferation
were observed in cells adjacent to or in close proximity
to but not in the Smo-expressing cells, demonstrating a
paracrine induction of proliferation by ectopic SMO
expression [27].
In studies of fibroblast growth factor receptor (FGFR)
signaling analogous to those performed with the steroid-
receptor chimeric outgrowths, deletion of both FGFRs
inhibited mammary ductal outgrowths and led to a loss of
the basal/MaSC population [28]. Surprisingly, a 10-fold ex-
cess of wild-type cells was able to rescue the FGFR1/2-null
cells. Intriguingly, in gain-of-function studies, activation of
FGFR1 has been shown to rapidly induce amphiregulin ex-
pression, and FGFR-induced tumorigenesis was shown to
Figure 1 Signaling interactions in mammary development and cancer. (A) An abbreviated view of paracrine interactions in mammary
development. Estrogen receptor alpha/progesterone receptor-positive (ERα/PR+) cells provide extrinsic cues to ERα/PR− cells to enable proliferation.
Hormone-specific paracrine mediators involve amphiregulin, which acts downstream of estrogen, and RANKL (receptor activator of nuclear factor kappa-B
ligand) and Wnt4, which act downstream of progesterone signaling. Other known paracrine mediators involve Wnts, fibroblast growth factors (FGFs),
insulin-like growth factor, bone morphogenetic proteins, transforming growth factor-beta (TGF-β), and Notch; however, owing to space limitations, not
all are depicted in this simple model. (B) Breast cancer subtypes reveal both inter- and intratumoral heterogeneity. Studies have identified interactions
between ERα+ cancer cells and ERα− cancer cells involving epidermal growth factor, FGF, and Notch interactions. The identification of signaling crosstalk
between cancer cell subpopulations within breast cancer subtypes remains a challenge, yet certain pathways have been identified, including PR/RANKL,
Wnt, Notch, and TGF-β. Further studies are required to elucidate the details of subtype-specific differences in paracrine signaling pathways. Cells
of the microenvironment (not depicted in this graphic) provide another layer of complexity and play an instrumental role in tumor progression
and heterogeneity. EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; MaSC, mammary stem cell; NF-κB, nuclear
factor kappa-light-chain-enhancer of activated B cell.
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ing [29]. Thus, both ER and FGFR appear to regulate
amphiregulin expression perhaps in luminal cells. Mem-
bers of the erbB family of receptors, such as erbB3, have
also been shown to be important regulators of the balance
of luminal and basal mammary epithelium [30]. ErbB3 isexpressed primarily in the luminal epithelium, and dele-
tion in the luminal but not the basal epithelium resulted in
growth of the basal cells, in part due to induction of cyto-
kines such as IL-6 in the luminal epithelial cells [30].
One of the most complicated paradigms to understand
with respect to mammary gland development and breast
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mammalian Wnt ligands, 10 frizzled receptors, and
other non-frizzled tyrosine kinase receptors like Ror1,
Ror2, and Ryk, together with co-receptors such as LRP5
and LRP6 that can signal through a variety of down-
stream pathways. The ligand-receptor context is viewed
as a key determinant of whether the Wnt signaling out-
put is through the canonical β-catenin-dependent path-
way or alternative non-canonical β-catenin-independent
pathways [31,32]. In addition, R-spondins and various
leucine-rich repeat containing G protein receptors are
expressed and play important roles in mammary gland
development, specifically with regard to stem cell func-
tion [32-34]. Many studies thus far have centered around
Wnt and stem cell function; however, Wnt ligands and
receptors exhibit striking specificity in their expression
throughout development. These observations highlight
the potential differential functions of Wnt pathway com-
ponents in luminal and basal cells in the mammary
gland and even within different subpopulations of cells
in breast cancer, specifically where Wnt signatures seem
to be evident in basal-like breast cancers [35,36]. Thus,
understanding the precise integration of signaling down-
stream of these ligands and receptors using genetic ap-
proaches remains a complicated task.
Wnt signaling is critical for mammary stem cell self-
renewal with unique developmental stage and time de-
pendencies [32,37,38]. Intriguingly, recent studies using
embryonic stem cells have suggested that localized Wnt
signals can orient asymmetric stem cell division [39]. In
the mammary gland, localized Wnt signaling most likely
plays a critical role in regulating the orientation of cell
division and the cellular fate during development. Add-
itionally, as with many signaling pathways, the activity of
the signaling event is not indicated simply by an ‘on or
off ’ state but is instead measured by the level and dur-
ation of the signaling [40]. Recent studies suggest that
elevated paracrine Wnt signals in the context of tumori-
genesis can exert distinct outcomes on the receiving
cells within breast xenograft models and emphasize the
challenge of deciphering Wnt interactions in vivo [41].
An understanding of the regulation of Wnt ligand ex-
pression by systemic hormones, the spatial and temporal
heterogeneity of ligand and receptor expression, and the
cell context dependence of Wnt signaling, therefore, will
be required before we will fully elucidate its role in
mammary gland development. Modeling these complex
cell-cell and paracrine interactions during normal devel-
opment will be an important prerequisite for developing
new therapies for breast cancer.
Paracrine signaling in breast cancer
Although the genetic and epigenetic landscape of a tumor
is immensely different than that of its normal counterpart,the cellular heterogeneity exhibited in tumors is strongly
influenced by cell-cell and paracrine interactions. The
concept that these developmental cues are intact and ac-
tive in the context of cancer is highlighted by studies in-
volving established breast cancer cell lines and cells from
patient tumors that display heterogeneity and respond to
both autocrine and paracrine mediators (Figure 1B). For
example, MCF-7 cells contain a small population of
ER− CD44+/CD24-ESA+ stem-like cells which can be
expanded through an estrogen-induced paracrine FGF/
FGFR/Tbx3 signaling pathway [42]. These authors con-
cluded that ‘breast cancer stem cells (CSCs) are stimulated
by estrogen through a signaling pathway that similarly
controls normal mammary epithelial stem cell biology’. In
studies using both established and primary ER+ primary
patient-derived cell lines, both the epidermal growth fac-
tor and Notch signaling pathways have also been shown
to operate downstream of estrogen in the regulation of
ER− CSCs [43]. Cytokine-induced and epigenetically regu-
lated NF-κB (nuclear factor kappa-light-chain-enhancer of
activated B cell) signaling in non-CSCs in triple-negative
breast cancer cell lines was shown recently to induce
jagged-1, which was then able to stimulate Notch signal-
ing in CSCs [44]. Other studies using primarily immortal-
ized and transformed human mammary epithelial cells, as
well as primary MECs isolated from reduction mammo-
plasties, revealed both paracrine and autocrine effects of
the Wnt and transforming growth factor-beta path-
ways on the interconversion between primary stem cell/
progenitor cell-enriched (basal) and lineage-restricted
(luminal) MECs [45]. These studies again support the
hypothesis that both normal and neoplastic epithelial
cells use very similar stem cell programs. They also
illustrate the need to study the properties of individual
cells and not total cell populations when performing both
high-throughput genetic and small-molecule screens
using breast cancer cell lines, which is now feasible with
high-content microscopy.
Conclusions
The above studies highlight the conservation of paracrine
signaling pathways in mice and women as well as in nor-
mal mammary gland development and breast cancer. In
normal development, precisely controlled positive and
negative feedback pathways regulate the level and duration
of signaling. However, in breast cancer, these feedback
loops are often disrupted, leading to sustained and in-
appropriately regulated signaling. The ability to model and
dissect these pathways genetically will be important for fu-
ture progress in devising new and improved combinatorial
therapeutic approaches for breast and other solid cancers.
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